KING PHARMACEUTICALS AND INYX ENTER INTO STRATEGIC ALLIANCE

King Pharmaceuticals, Inc. (NYSE: KG) and Inyx, Inc. (OTC Bulletin Board: IYXI) announced today that they have entered into a strategic collaboration relating to Intal(R) (cromolyn sodium) and Tilade(R) (nedocromil sodium), which includes the continued development of a new formulation of Intal(R) utilizing hydrofluoroalkane (HFA), an environmentally friendly propellant. Intal(R) and Tilade(R) are King's currently marketed inhaled anti-inflammatory agents for the management of asthma.

PRNewswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-08-2005/0004103435&EDATE=)